Page last updated: 2024-11-04

sulfinpyrazone and Cytokine Release Syndrome

sulfinpyrazone has been researched along with Cytokine Release Syndrome in 1 studies

Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.

Cytokine Release Syndrome: A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Abo Elmaaty, A1
Hamed, MIA1
Ismail, MI1
B Elkaeed, E1
S Abulkhair, H1
Khattab, M1
Al-Karmalawy, AA1

Other Studies

1 other study available for sulfinpyrazone and Cytokine Release Syndrome

ArticleYear
Computational Insights on the Potential of Some NSAIDs for Treating COVID-19: Priority Set and Lead Optimization.
    Molecules (Basel, Switzerland), 2021, Jun-21, Volume: 26, Issue:12

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Auranofin; Binding Sites; Computational B

2021
chemdatabank.com